Moreover, the injection of LY294002, a PI3K inhibitor, reversed this process (84), suggesting that Apelin-13 might improve glucose and lipid metabolism, reduce oxidative stress and inflammation, and improve GDM by activating the PI3K/Akt signaling pathway. Here, AKT1 is linked to gestational diabetes.